Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-hodgkin's lymphoma or multiple myeloma

Clinical Pharmacokinetics

Volumn 48, Issue 3, 2009, Pages 199-209

  Quinn, David I ^a,i   Nemunaitis, John ^b   Fuloria, Jyotsna ^c   Britten, Carolyn D ^d   Gabrail, Nashat ^e   Yee, Lorrin ^f   Acharya, Milin ^g   Chan, Kai ^g   Cohen, Nadine ^g   Dudov, Assen ^h  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Mary Crowley Medical Research Center   (United States)

^c Oschner Clinic   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Gabrail Cancer Center   (United States)

^f Northwest Medical Specialties   (United States)

^g JOHNSON AND JOHNSON   (United States)

^h Sofia Cancer Centre   (Bulgaria)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; BORTEZOMIB; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; LOPERAMIDE; OMEPRAZOLE;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; COORDINATION DISORDER; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPOTENSION; INSOMNIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORTHOSTATIC HYPOTENSION; PARAPLEGIA; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; SUPRAVENTRICULAR PREMATURE BEAT; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VERTIGO; VOMITING; WEIGHT REDUCTION;

AGED; ANTI-ULCER AGENTS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BORONIC ACIDS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS; OMEPRAZOLE; PROTON PUMP INHIBITORS; PYRAZINES;

EID: 65349107174     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200948030-00006     Document Type: Article

References (49)

1. Blume H, Donath F, Warnke A, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006; 29 (9): 769-84
2. Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 2001 May; 13 (5): 611-6
3. McLeod HL. Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol 1998 Jun; 45 (6): 539-44
4. Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol 2004 Aug; 5 (8): 489-96
5. Blower P, de WR, Goodin S, et al. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol 2005 Aug; 55 (2): 117-42
6. Egger T, Dormann H, AhneG, et al. Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. DrugsAging 2003; 20 (10): 769-76
7. Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther 2007 Apr; 32 (2): 169-75
8. Janchawee B, Wongpoowarak W, Owatranporn T, et al. Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand. J Clin Pharm Ther 2005 Feb; 30 (1): 13-20
9. Thjodleifsson B. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors. Drugs Aging 2002; 19 (12): 911-27
10. MacLeod SL, Nowell S, Massengill J, et al. Cancer therapy and polymorphisms of cytochromes P450. Clin Chem Lab Med 2000 Sep; 38 (9): 883-87
11. Uttamsingh V, Lu C, Miwa G, et al. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos 2005; 33 (11): 1723-8
12. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4 (5): 349-60
13. Voorhees PM, Dees EC, O'Neil B, et al. The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9 (17): 6316-25
14. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8 (8): 2505-11
15. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006 Sep; 24 (30): 4867-74
16. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23 (4): 667-75
17. O'Connor O, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23 (4): 676-84
18. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20 (22): 4420-7
19. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22 (11): 2108-21
20. Richardson P, Sonneveld P, Schuster M, et al. Bortezomib continues to demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: updated results of the APEX trial [abstract]. Blood 2005; 106: 715a
21. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl JMed 2005; 352 (24): 2487-98
22. Fanucchi MP, Fossella FV, Belt R, et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006 Nov; 24 (31): 5025-33
23. Velcade- (bortezomib) for injection: US prescribing information. Cambridge (MA): Millennium Pharmaceuticals, Inc., 2006 Dec
24. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975- 2002 [online]. Available from URL: http://seer.cancer.gov/csr/1975-2002/ [Accessed 2006 Jun 15]
25. Lenz G, Dreyling M, Hiddemann W. Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 2004; 83 (2): 71-7
26. Labutti J, Parsons I, Huang R, et al. Oxidative deboronation of the peptide boronic acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome P450 reaction. Chem Res Toxicol 2006 Apr; 19 (4): 539-46
27. Pekol T, Daniels JS, Labutti J, et al. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos 2005; 33 (6): 771-7
28. Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005 Jun; 20 (3): 153-67
29. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006 Jul; 44 (7): 297-302
30. Ko JW, Sukhova N, Thacker D, et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997 Jul; 25 (7): 853-62
31. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31-41
32. US National Cancer Institute. Common terminology criteria for adverse events, v3.0 (CTCAE) [online]. Available from URL: http://ctep.cancer. gov/forms/CTCAEv3.pdf [Accessed 2008 Nov 26]
33. Lightcap ES, McCormack TA, Pien CS, et al. Proteasome inhibition measurements: clinical application. Clin Chem 2000; 46 (5): 673-83
34. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977 Dec; 74 (12): 5463-7
35. Schaeffeler E, Schwab M, Eichelbaum M, et al. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat 2003 Dec; 22 (6): 476-85
36. Watson DE, Li B. TaqMan applications in genetic and molecular toxicology. Int J Toxicol 2005 May; 24 (3): 139-45
37. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41 (12): 913-58
38. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997 Feb; 60 (2): 284-95
39. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001 Apr; 27 (4): 383-91
40. Stewart AK, Sullivan D, Lonial S, et al. Pharmacokinetic (PK) and pharmacodynamics (PD) study of two doses of bortezomib (Btz) in patients with relapsed multiple myeloma (MM) [abstract]. Blood 2006; 108: 1008a
41. Dy GK, Thomas JP, Wilding G, et al. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res 2005; 11 (9): 3410-6
42. Blaney SM, Bernstein M, Neville K, et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 2004; 22 (23): 4804-9
43. Hamilton AL, Eder JP, Pavlick AC, et al. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 2005; 23 (25): 6107-16
44. Lara Jr PN, Koczywas M, Quinn DI, et al. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol 2006 Feb; 1 (2): 126-34
45. Aghajanian C, Dizon DS, Sabbatini P, et al. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 2005 Sep; 23 (25): 5943-9
46. Ryan DP, O'Neil BH, Supko JG, et al. A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 2006 Dec; 107 (11): 2688-97
47. Ryan DP, Appleman LJ, Lynch T, et al. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer 2006 Nov; 107 (10): 2482-9
48. Messersmith WA, Baker SD, Lassiter L, et al. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 2006; 12 (4): 1270-5
49. Chatta GS, Rader ME, Belani CP, et al. Effect of ketoconazole administration on the pharmacokinetics (PK) and pharmacodynamics (PD) of bortezomib in patients with advanced solid tumors [abstract]. J Clin Oncol 2007; 25: 609s